کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Original Article

Visual acuity in an Iranian cohort of patients with type 2 diabetes: the role of nephropathy and ischemic heart disease

Negar Horri\textsuperscript{a}, Mahboube Farmani\textsuperscript{a}, Mahmoud Ghassami\textsuperscript{b}, Sassan Haghighi\textsuperscript{a*}, Massoud Amini\textsuperscript{c}

Abstract

BACKGROUND: The aim of this study was to investigate the risk factors of low vision in type 2 diabetic patients and the prevalence of ischemic heart diseases and nephropathy for different visual acuities.

METHODS: In this cross-sectional study, data from 738 type 2 diabetic patients including evidences for nephropathy and ischemic heart disease, demographic characteristics, blood pressure and body mass index were collected, and then patients were divided into 3 groups based on their best corrected visual acuity in the better-seeing eye. Analysis of variance was used to compare basic characteristics according to different levels of visual acuity.

RESULTS: The prevalence of blindness and low vision was 5.5% and 13.3% respectively, and as age, duration of diabetes, systolic blood pressure and body mass index increased, the visual acuity decreased. The prevalence of hypertension and obesity in patients with visual disabilities was significantly higher than in patients with not impaired visions (p = 0.008 and p = 0.02, respectively). We also found that with greater decline in visual acuity, the prevalence of nephropathy and ischemic heart diseases increased.

CONCLUSIONS: The factors related to retinopathy play a role in affecting the degree of visual impairment in diabetic patients. Therefore, controlling risk factors can be useful in decreasing impairment of vision and blindness.

KEYWORDS: Diabetes Mellitus, Type 2, Visual Acuity, Diabetic Retinopathy, Blindness, Diabetic Nephropathies, Cardiovascular Diseases.

Diabetes mellitus is one of the most common non-communicable diseases in the world. The WHO has predicted that, "the number of diabetic patients in the world will reach 300 millions by 2025, and more than 75% of these patients will be living in developing countries."\textsuperscript{1}

Diabetic retinopathy is one of the most common complications of diabetes,\textsuperscript{2} and one of the leading causes of blindness and visual impairment.\textsuperscript{3-6}

According to statistics from a decade ago, 40 million people were blind and 110 million had low vision.\textsuperscript{7} The American Diabetes Association claims that diabetes is responsible for 8% of legal blindness.\textsuperscript{8}

Diabetic retinopathy and resulting blindness are responsible for a major disability in patients, and they lead to a high financial and social burden on the community indicating the importance of increased efforts in this field.

Diabetic retinopathy is the principal cause of one-third of all cases of blindness,\textsuperscript{9} and also, according to some trials, a factor which is asso-
associated to increased prevalence of cardiovascular diseases.\textsuperscript{10-12} These trials supposed that the pathogenesis of diabetic retinopathy and cardiovascular diseases are both microvascular.

On the other hand, microalbuminuria which is another microvascular complication of diabetes has a connection with both, the development and progression of retinopathy.\textsuperscript{13}

Taking into account the possibility that retinopathy, nephropathy and cardiovascular diseases may have similar pathogenesis in diabetic patients, and considering the role of retinopathy on vision acuity,\textsuperscript{14-16} it can be assumed that the prevalence of chronic complications of diabetes is different for different visual acuities, and risk factors related to diabetic retinopathy are possibly connected to visual impairment in diabetic patients. Since there are limited data on this field in Iran, and considering the fact that these data are essential for setting up of Iranian blindness prevention program, and also the clear effect of early screening and suitable intervention on reducing incidence of blindness and low vision related to diabetic retinopathy,\textsuperscript{17,18} this study was performed in an Iranian population of type 2 diabetic patients at the Isfahan Endocrine and Metabolism Research Center. Study protocol was approved by the ethics committee of the center (Project No. 87015). The study complied with the current version of the Declaration of Helsinki.

For this study we used routinely collected and registered data from patients registered at this center. These data were initially collected by an endocrinologist and subsequently via next follow-up visits to physicians at the center, and then the standard check lists that were filled out by these persons entered into the central computer system of the center.

This information included: demographic characteristics, past history, family history, blood pressure, lipid profile, blood urea nitrogen (BUN), creatinin, HbA1c (glycosylated hemoglobin), urine albumin, the results of eye exams and of cardiovascular follow-ups.

Lipid profile, BUN, creatinin, BP and body weight were usually monitored monthly and the ophthalmic, cardiovascular and renal condition of patients at least yearly.

All lab tests were performed by the laboratory at the Endocrine and Metabolism Research Center. HbA1c was measured by spectrophotometer (DS5) and urine albumin by the sopt collection method. Creatinin was measured by the photometric method and albumin by the imunoturbidimetric method on a DB 3000 appliance.

Eye Examination
Eye examination was performed by an experienced ophthalmologist and included: testing of visual acuity (VA), corrected and uncorrected visual acuities were determined using a Snellen chart and a Canon autorefractometer (R-50m, Japan), best corrected visual acuity (BCVA) was defined as the visual acuity after subjective refraction in the better eye, and also intraocular pressure was measured using Goldman applanation tonometry (Haag-streit AG1A 900, Switzerland).

The pupil of each eye was dilated using tropicamide 1% followed by a dilated fundus examination using a 78-dioptre non-contact fundus viewing lens (Volk). If needed, indirect ophthalmoscopy was performed. All findings were registered in special checklists.

Cardiac Condition Follow-Up
Ischemic heart disease was diagnosed by taking history and an ECG test. If there were electrocardiographic abnormalities as diagnosed by the Minesota-code or symptoms of ischemic heart disease,\textsuperscript{19} the patient was referred to a
cardiologist for the exercise tolerance test and other diagnostic and therapeutic procedures.

Patients
Our target population was type 2 diabetic patients of Isfahan. As it has been mentioned before, the center covers 40% of diabetic patients of Isfahan. Between 2008 and 2009, 1300 diabetic patients came to the center for their follow-up visits. Of these patients, 1000 persons had type 2 diabetes and 300 persons had type 1.

For this study we used data collected from 900 conveniently-selected patients with type 2 diabetes who had a complete eye exam during that period. Patients with incomplete records on their ophthalmologic exam or on evidences of nephropathy and ischemic heart disease were excluded from the study.

Definitions
The patients were divided into 3 groups based on their best corrected visual acuity (BCVA) in the better seeing eye, using the North American definition.20

**Best Corrected Visual Acuity:** Not impaired was defined as best corrected visual acuity better than or equal to 20/40 (5/10), low vision as worse than 20/40 but better than 20/200 (2/10-4/10) and blind was defined as 2/200 or worse (1/10 or worse).

**Ischemic Heart Disease:** The patients who have been put on treatment or undergone surgery like coronary artery bypass graft (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) after diagnostic tests.

**Nephropathy:** Urine albumin/creatinin more than 30mg/g.21

**Hypertension:** (in diabetic patients) Systolic/diastolic blood pressure ≥ 130/80 mmHg.22

**Obesity:** Body mass index (weight in kg/squared of height in m) ≥ 30 kg/m².23

Statistical Analysis
We used t-test to compare continuous variables, chi-square test to compare categorical variables, and analysis of variance (ANOVA) test to compare basic characteristics according to different levels of visual acuity. In all instances, p values < 0.05 were considered significant. Data analyses were done using the SPSS version 13 (Chicago, USA).

Results
Of the 900 investigated files, 162 were excluded because of incomplete information. The study included data from 738 patients. Of these patients with the mean age of 60.29 ± 10.3 years, 41 patients (5.5%) were blind (95% Confidence Interval (CI): 2.5-13.2) and 98 patients (13.3%) had low vision, (95% CI: 4.3-32.3).

Tables 1 and 2 show the demographic characteristics for patients divided into 3 groups and results of post hoc tests for continuous variables among 3 groups of patients with different visual acuities, respectively. According to these data, there was a significant difference among 3 groups in terms of mean age, body mass index (BMI), duration of diabetes and systolic blood pressure. Presence of any of the following conditions was associated with corresponding decrease in visual acuity: increasing age, longer duration of diabetes, higher systolic blood pressure, and increased body mass index.

Table 3 shows the prevalence of different levels of visual acuity by the presence of hypertension or obesity. According to this table, when patients in blind and low vision groups are considered together, it is evident that 20.3% of hypertensive patients and 5.5% of non-hypertensive ones have visual disability (p = 0.008), and 22.9% of obese patients and 16.2% of non-obese ones have visual impairment (p = 0.02).

Table 4 shows the prevalence of ischemic heart diseases (IHD) and nephropathy in 3 groups.

Considering these data, there is a significant difference between the 3 groups in terms of the prevalence of IHD and nephropathy.
Table 1. Basic clinical and demographic characteristics and mean of HbA1c of patients with different visual acuities

|                     | Blind n = 41 | Low vision n = 48 | Not impaired n = 599 | Total n = 738 |
|---------------------|--------------|-------------------|----------------------|--------------|
| Male                | 82.9%        | 68.7%             | 69.1%                | 69.8%        |
| Female              | 17.1%        | 31.3%             | 30.9%                | 30.2%*       |
| Age† (Year)         | 66.15 ± 10.28| 65.78 ± 8.62      | 59.00 ± 10.14        | 60.29 ± 10.31** |
| BMI‡ (kg/m²)        | 31.03 ± 5.26 | 29.37 ± 4.91      | 29.06 ± 4.48         | 29.21 ± 4.60*** |
| Duration of diabetes‡ (Year) | 20.19 ± 8.02 | 17.24 ± 7.35     | 14.11 ± 6.46         | 14.87 ± 6.88*** |
| HbA1c (%)           | 7.69 ± 1.86  | 7.54 ± 2.03       | 7.67 ± 1.67          | 7.65 ± 1.73*  |
| Systolic blood pressure† (mmHg) | 128.78 ± 18.26 | 123.47 ± 16.47 | 120.35 ± 16.65       | 121.23 ± 16.83§ |
| Diastolic blood pressure† (mmHg) | 77.80 ± 7.9 | 75.82 ± 9.41      | 75.83 ± 9.47         | 75.94 ± 9.38*  |

Blind: Best corrected visual acuity (BCVA) 1/10 or worse
Low vision: BCVA worse than 4/10 but better than 2/10
Not impaired: BCVA better than 4/10
† Mean ± SD
‡ Body Mass Index
* P > 0.05
** P < 0.001
*** P < 0.05
§ P < 0.01

Table 2. Results of post hoc tests for basic clinical and demographic characteristics and mean of HbA1c among 3 groups of patients with different visual acuities

|                     | B* and LV** (P value) | B and NI*** (P value) | LV and NI (P value) |
|---------------------|-----------------------|-----------------------|---------------------|
| Age (year)          | 0.980                 | 0.000                 | 0.000               |
| BMI† (kg/m²)        | 0.153                 | 0.029                 | 0.820               |
| Duration of diabetes (year) | 0.060                | 0.000                 | 0.000               |
| HbA1c (%)           | 0.893                 | 0.995                 | 0.805               |
| Systolic blood pressure (mmHg) | 0.233                | 0.008                 | 0.231               |
| Diastolic blood pressure (mmHg) | 0.523                | 0.429                 | 1.000               |

*B: Blind
** LV: Low vision
*** NI: Not impaired
† Body Mass Index
Table 3. Prevalence of different levels of visual acuity in type 2 diabetic patients with and without hypertension or obesity

|                  | Blind† | Low vision‡ | Not impaired§§ | Total (n=738) |
|------------------|--------|-------------|-----------------|---------------|
| With hypertension‡‡ |        |             |                 |               |
| n = 40           | 6%     | 14.3%       | 79.7%           | 100%          |
|                  | n = 95 |             |                 |               |
|                  | 1.4%   | 4.1%        | 94.6%           | 100%*         |
| Without hypertension | 8.2% | 14.7%       | 77.1%           | 100%          |
| n = 1            | n = 3  | n = 70      |                 | n = 74        |
| Obese†           |        |             |                 |               |
| n = 24           | 3.8%   | 12.4%       | 83.8%           | 100%**        |
| Non obese        | n = 17 | n = 55      |                 | n = 445       |

† Blind: Best corrected visual acuity (BCVA) 1/10 or worse
‡ Low vision: BCVA worse than 4/10 but better than 2/10
§§ Not impaired: BCVA better than 4/10
‡‡ Hypertension (diabetic patients): Systolic/diastolic blood pressure ≥ 130/80 mmHg
* χ² = 9.687, p < 0.01
** χ² = 7.695, p < 0.05

The prevalence of nephropathy is significantly higher in the group with blindness than in both groups with not impaired vision (p = 0.003) and those with low vision (p = 0.01). Also the prevalence of IHD was significantly lower in patients with not impaired vision than those with visual disabilities.

Table 4. Prevalence of ischemic heart disease and nephropathy in 3 groups of type 2 diabetic patients with different levels of visual acuity

|                  | Blind† | Low vision‡ | Not impaired§§ | Total |
|------------------|--------|-------------|-----------------|-------|
|                  | n = 41 | n = 98      | n = 599         | n = 738 |
| Nephropathy‡‡     |        |             |                 |       |
| n = 41           | 100%   | 83.7%       | 82%             | 83.2%* |
|                  | n = 82 |             |                 |       |
|                  | n =491 | n =614      |                 |       |
| IHD†             |        |             |                 |       |
| n = 16           | 39%    | 34.7%       | 20.5%           | 23.4%** |
|                  | n = 34 |             |                 |       |
|                  | n =123 | n =173      |                 |       |

† Blind: Best corrected visual acuity (BCVA) 1/10 or worse
‡ Low vision: BCVA worse than 4/10 but better than 2/10
§§ Not impaired: BCVA better than 4/10
‡‡ Nephropathy: Urine albumin/creatinine > 30mg/g
† Ischemic heart diseases
* χ² = 8.751, p < 0.05
** χ² = 15.283, p < 0.001
Discussion
In this cross-sectional study carried out on 738 registered type 2 diabetic patients, the prevalence of blindness and low vision was 5.5% and 13.3%, respectively. It was observed that the visual acuity decreased with increasing age, duration of diabetes, systolic blood pressure, and body mass index. It was also showed that with greater decline in visual acuity, the prevalence of nephropathy and ischemic heart diseases increased.

Reported prevalence of blindness and low vision is very different in various societies. The prevalence of blindness in type 2 diabetic patients in Yemen was 16%, in Taiwan was 1.6%, in Denmark was 1.5%, and in England was 1.16%. It has been claimed by the Center for Disease Control that among adults with diabetes, 2.9% suffered from mild vision impairment and 1% had severe visual impairment after correction.

One reason for the higher prevalence of visual impairment and blindness in our study in comparison with other studies was the nature and the type of groups studied. The Taiwan study was a population-based diabetic retinopathy screening program. The study in England was a population-based study of diabetic patients in a district in the northwest of England. The Denmark study included blind cases registered in a database of diabetic patients, but our study has been carried out at a referral center for diabetic patients, which is affiliated to Isfahan University of Medical Sciences, and the prevalence of each chronic complication may be affected by this referral pattern, because the number of patients with more severe complications is greater, they also make more frequent visits and are more vigilant.

Other possible reasons for high prevalence of low vision and blindness in our study was primarily the long duration of diabetes (more than 15 years in 30.5%) and secondly, high prevalence of hypertension and nephropathy (89.8% and 83% respectively) in our studied population.

Different studies claimed that, the duration of diabetes, age, high blood pressure, and albuminuria are directly related to the onset and progression of diabetic retinopathy, and diabetic retinopathy is one of the major causes of visual impairment in diabetic patients, so it is reasonable to suppose that risk factors related to it are also related to the status of visual acuity.

The results of our research revealed that our supposition was well-founded, and age, duration of diabetes, body mass index and systolic blood pressure were also related to the severity of visual impairment. In addition, in our study, hypertension and obesity were significantly more prevalent in patients with visual disabilities than in patients with unimpaired visions. Some other trials have also shown that there is a relationship between systolic blood pressure and diabetic retinopathy, and have claimed that the severity of retinopathy in type 2 diabetic patients is positively associated with systolic blood pressure and body mass index.

In our study there was no relationship between different levels of visual acuity and sex. In an independent study in Isfahan, Janghori-bani et al also reached the conclusion that there was no association between retinopathy and sex, which was in agreement with the results of other studies.

We also found a relationship between severity of visual impairment and prevalence of ischemic heart disease and nephropathy.

In the Ossama et al study, there was also a relationship between ischemic heart disease and retinopathy, but after adjustment for risk factors, the relationship was no longer significant. A limited number of studied ischemic heart disease cases (44/500) was mentioned as the possible reason for this finding, but in our study, the number of ischemic heart disease cases was not limited (Table 4); so, it seems that the prevalence of ischemic heart disease does not have an independent relationship with visual acuity. The reason is possibly the difference in pathogenesis of ischemic heart disease and retinopathy; the former is macrovascular in nature and the latter has a microvascular pattern. Nephropathy, which was in direct relationship with visual acuity has also a
Microvascular basis.

We are fortunate at our center to have access to some of the most comprehensive data of its kind in the developing world. Based upon information from earlier studies, it is clear that our patients are a representative sample of known diabetics in Isfahan.\(^{32,37}\) In addition, a positive aspect of our diagnosis of ischemic heart disease, nephropathy, hypertension and obesity was that it has not been based on a single examination but on continued examinations during follow-ups. However, this study has also some limitations. The study was of course clinic-based rather than population-based. Clinic-based estimates of the prevalence of complications are most likely to be affected by referral patterns, since patients at our clinic are more likely to have complications, and it has been showed by experience that once a complication occurs, patients are more likely to come regularly for treatment, and this factor affects the estimated prevalence of complications. Considering the above-mentioned reasons, it seems that a population-based study will be needed regarding the matter in the future.

Conclusion

The factors related to retinopathy play a role in affecting the degree of visual impairment in diabetic patients. Considering the fact that the high prevalence of low vision is a serious threat to the health of diabetic patients in Isfahan, control of risk factors can be useful in decreasing impairment of vision and blindness.

Acknowledgements

The authors would like to thank Ms. Zahra Khani, Mrs. Mehri Foroughifar and Mr. Abyar for their technical assistance in computer affairs.

Conflict of Interests

Authors have no conflict of interests.

Authors' Contributions

NH was the principal investigator of the research project, carried out the design, coordinated the study, participated in all of the research stages, and also in manuscript preparation. MF assisted in designing the study and coordinated and assisted in carrying out all the research stages. MG assisted in designing the study and assisted in carrying out the research. SH assisted in designing the study, coordinated in carrying out the research, and participated in manuscript preparation and revision. MA assisted principally in designing the study and participated in manuscript preparation and revision.

References

1. Khatib Oussama MW. Guidelines for the Prevention, Management and Care of Diabetes Mellitus. Cairo: WHO Regional Office for the Eastern Mediterranean; 2006. 81 p.
2. Davidson MB. The continually changing natural history of diabetes mellitus. J Chronic Dis. 1981; 34(1): 5-10.
3. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989; 5(7): 559-70.
4. Kahn HA, Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol. 1974; 78(1): 58-67.
5. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983; 67(4): 209-13.
6. Munier A, Gunning T, Kenny D, O’Keefe M. Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol. 1998; 82(6): 630-3.
7. Thylefors B, Negrel AD, Parajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ. 1995; 73(1): 115-21.
8. American Diabetes Association: facts and figures: Diabetes and Eye Disease [article online], 2003, Available from http://WWW.Diabetes.Org/main/info/facts/eye/default. JSP. Accessed June 20, 2009.
9. American Diabetes Association. Diabetic retinopathy. Diabetes Care 1998; 21: 157-9.
10. Targher G, Bertolini L, Zenari L, Lippi G, Pichirit I, Zoppinit G, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events among type 2 diabetic patients. Diabet Med 2008; 25(1): 45-50.

11. Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G. Retinopathy predicts future cardiovascular events among type 2 diabetic patients. Diabetes Care 2006; 29(5): 1178.

12. Cheung N, Wang JJ, Klein R, Coper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007; 30(7): 1742-6.

13. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Risk factors for incident retinopathy in a diabetic and non diabetic population: The Hoorn Study. Arch ophthalmol 2003; 121(2): 245-51.

14. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology 1988; 95(10): 1875-95.

15. Keen H. Prevalence of blindness in diabetics. J Roy Coll Physicians London. 1972; 7(1): 53-60.

16. Dwyer MS, Melton LJ III, Ballard DJ, Palumbo PY, Trautmann JC. Chu CP. Incidence of diabetic retinopathy and blindness: A population – based study in Rochester, Minnesota. Diabetes Care 1985; 8(4): 316-22.

17. Dwyer MS, Melton LJ III, Ballard DJ, Palumbo PY, Trautmann JC. Chu CP. Incidence of diabetic retinopathy and blindness: A population – based study in Rochester, Minnesota. Diabetes Care 1985; 8(4): 316-22.

18. Sundling V, Gulbrandsen P, jervell J, Straand J. Care of vision and ocular health in diabetic members of a national diabetes organization: a cross sectional study. BMC Health Serv Res 2008; 8: 159.

19. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. The World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28(8): 615-40.

20. Maberley DAL, Hollands H, Chang A, Adilman S, Chakraborti B, Kliever G. The prevalence of low vision and blindness in a Canadian inner city. Eye (Lond) 2007; 21(4): 528-33.

21. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346(8982):1080-4.

22. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32 (Suppl. 1): S6–S12.

23. Filer JS, Filer EM. Obesity. In: Kasper DL, editors. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2005. p. 422-9.

24. Bamashmus MA, Gunaid AA, khaneekar RB. Diabetes retinopathy, visual impairment and ocular status among patients with diabetes mellitus in Yemen : A hospital – based study. Indian J Ophthalmol 2009; 57(4): 293-8.

25. Tung TH, Liu JH, Lee FL, Chen SJ, Li AF, Chou P. Population – Based study of nonproliferative diabetic retinopathy among type 2 diabetic patients in Kinmen, Taiwan. Jpn J ophthalmol 2006; 50(1): 44-52.

26. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner Jk, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health care reform. Diabetes care 1994; 17(8): 909-17.

27. Backlund LB, Algvere PV, Rosenqvist U. New blindness in diabetes reduced by more than one – third in Stockholm County. Diabet Med 1997; 14(9): 732-40.

28. Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Prevalence of blindness and visual impairment in a population of people with diabetes. Eye (Lond) 2001; 15(Pt 5): 640-3.

29. Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Prevalence of blindness and visual impairment in a population of people with diabetes. Eye (Lond) 2001; 15(Pt 5): 640-3.

30. Zhang X, Gregg EW, Cheng YJ, Thompson T, Geiss LS, Quenas MR. Correctable visual impairment among persons with diabetes – United States, 1999 – 2004. JAMA 2007; 297(1): 34-6.

31. el Haddad OAW, Saad MK. Prevalence and risk factors for diabetic retinopathy among Omani diabetics. Br J Ophthalmol 1998; 82(8): 901-6.

32. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner Jk, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health care reform. Diabetes care 1994; 17(8): 909-17.

33. Backlund LB, Algvere PV, Rosenqvist U. New blindness in diabetes reduced by more than one – third in Stockholm County. Diabet Med 1997; 14(9): 732-40.

34. McFarland B, Filer EM. Obesity. In: Kasper DL, editors. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2005. p. 422-9.

35. Bamashmus MA, Gunaid AA, khaneekar RB. Diabetes retinopathy, visual impairment and ocular status among patients with diabetes mellitus in Yemen : A hospital – based study. Indian J Ophthalmol 2009; 57(4): 293-8.

36. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner Jk, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health care reform. Diabetes care 1994; 17(8): 909-17.

37. el Haddad OAW, Saad MK. Prevalence and risk factors for diabetic retinopathy among Omani diabetics. Br J Ophthalmol 1998; 82(8): 901-6.

38. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner Jk, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health care reform. Diabetes care 1994; 17(8): 909-17.

39. Backlund LB, Algvere PV, Rosenqvist U. New blindness in diabetes reduced by more than one – third in Stockholm County. Diabet Med 1997; 14(9): 732-40.
کارگاههای آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله